Physician profile
Atul Gupta
NPI 1790826063
$2,004.15
in general payments reported to CMS, 2019-2025
14 companies · $14.38 in 2025
The $14.38 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $98.71 · 2021: $352 · 2022: $452 · 2023: $654 · 2024: $98.02 · 2025: $14.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $558.75 | 2019-2023 | Dificid, Zerbaxa, Recarbrio |
| Abbvie INC. | $440.25 | 2021-2024 | |
| Viiv Healthcare Company | $307.75 | 2019-2024 | Cabenuva, Dovato |
| Melinta Therapeutics, LLC | $167.01 | 2019-2024 | Orbactiv, Kimyrsa, Rezzayo |
| Gilead Sciences, INC. | $151.55 | 2019-2021 | |
| Insmed, INC. | $145.02 | 2019-2023 | Arikayce |
| Astellas Pharma US INC | $77.83 | 2019-2024 | Cresemba |
| Allergan, INC. | $59.27 | 2019-2020 | |
| Horizon Therapeutics Plc | $18.61 | 2023 | Actimmune |
| Paratek Pharmaceuticals, INC. | $17.88 | 2022 | |
| Nabriva Therapeutics, Plc | $15.82 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $15.81 | 2020 | |
| Philips North America LLC | $14.38 | 2025 | Multi Modality Ivus Other Systems |
| Electromed, INC. | $14.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.